

PROGRAMME - TUESDAY 23 MARCH 2027

09.00-09.15 Welcome and introduction

Summit Chair: Benjamin Besse – Institut Gustave Roussy, France
Summit Co-Chair: Elena Garralda – Vall d’Hebron Institute of Oncology, Spain

09:15-12:45 Track 1 – Data Science & Artificial Intelligence

Track Co-Chairs:

Vassilis Golfinopoulos – EORTC, Belgium
Jeroen Lemaire – In The Pocket, Belgium

09:15-10:45 Session 1: Data and AI in clinical sciences

- 09:15-09:45 Towards virtual patient: AI for accelerating medical discovery
Hoifung Poon – Microsoft Health Futures, USA
- 09:45-10:05 The AI transformation of clinical care
Rudolf Fehrmann – University Medical Center Groningen, the Netherlands
- 10:05-10:45 Panel discussion: The technology isn't the change: How AI will transform our practice
Including Alina Helsloot – Elsevier, the Netherlands

10:45-11:15 Coffee break

11:15-12:45 Session 2: Applied AI: From the technology lab to application

- 11:15-11:35 Opportunities for accelerating clinical research
Cristina Durán – Evinova, Switzerland
- 11:35-11:55 Lessons from advanced automotive technology
Jonas Ambeck-Madsen – Toyota Motor Europe, Belgium
- 11:55-12:45 Panel discussion: Balancing opportunities and risks in AI innovation
Including Niels Vandervoort – Johnson & Johnson Innovative Medicine, Belgium

12:45-14:00 Poster viewing / Lunch

14:00-17:30 Track 2 – Quality of Life & Patient Centricity

Track Co-Chairs:

Madeline Pe – EORTC, Belgium

Ananda Plate – WECAN (Workgroup of European Cancer Patient Advocacy Networks), Germany

14:00-15:30 Session 3: Strengthening the value of patient experience data for decision-making

14:00-14:15 The importance of Patient-Reported Outcomes (PROs) and patient preferences
Jan Geissler – PatVOCATES, Germany

14:15-14:30 PROs to assess benefits and harms of cancer treatments
Martin Stockler – University of Sydney, Australia

14:30-14:45 Patient preferences to assess the benefit and harms trade-off
Francesco Pignatti – EMA, the Netherlands

14:45-15:00 The value of PROs in Health Technology Assessment (HTA) for comparative effectiveness/comparative safety
Lisa Vervueren – RIZIV/INAMI, Belgium

15:00-15:30 Panel discussion
including Jens Lehmann – LVR-University Hospital Essen, Germany

15:30-16:00 Poster viewing / Coffee break

16:00-17:30 Session 4: What's next: Assessing patient experience through digital health & remote monitoring

16:00-16:15 ePROs and visualisation tools for patients: making PROs more useful for patients
Bernhard Holzner – Innsbruck Medical University, Austria

16:15-16:30 From data to decision: using wearables and PROs to enable timely intervention in cancer trials
Bill Byrom – Signant Health, United Kingdom

16:30-16:45 Ethics and perspectives on digital health/remote monitoring
Tarec Christoffer El-Galaly – Aarhus University, Denmark

16:45-17:00 Remote monitoring to assess patients' outcomes – which direction should these developments go?
Speaker tbc

17:00-17:30 Panel discussion
including Jens Lehmann – LVR-University Hospital Essen, Germany

17:30-18:30 Poster viewing / Welcome reception

PROGRAMME - WEDNESDAY 24 MARCH 2027

09:00-12:30 Track 3 – Methodology
RECIST: Measuring what matters in modern oncology

Track Co-Chairs:

Saskia Litière – EORTC, Belgium and Elena Garralda – Vall d’Hebron Institute of Oncology, Spain

09:00-10:30 Session 5: Evidence, expectations, and the path forward

- | | |
|-------------|--|
| 09:00-09:10 | Setting the scene: why RECIST matters
<i>Elena Garralda – Vall d’Hebron Institute of Oncology, Spain</i> |
| 09:10-09:25 | Can we do better than one dimension?
<i>Raquel Perez-Lopez – Vall d’ Hebron Institute of Oncology, Spain</i> |
| 09:25-09:40 | PET and RECIST – to PERCIST or not?
<i>Ronald Boellaard – Amsterdam UMC, the Netherlands</i> |
| 09:40-09:55 | Liquid biopsy (ctDNA) for monitoring response and progression in solid tumour patients
<i>Klaus Pantel – UKE Hamburg, Germany</i> |
| 09:55-10:30 | Panel discussion |

10:30-11:00 Poster viewing / Coffee break

Track Co-Chairs:

Saskia Litière – EORTC, Belgium and Elisabeth G.E. de Vries – UMCG, the Netherlands

11:00-12:30 Session 6: From response assessment to clinical decision-making

- | | |
|-------------|--|
| 11:00-11:05 | RECIST 2.0 – The road ahead
<i>Elisabeth G.E. de Vries – UMCG, the Netherlands</i> |
| 11:05-11:20 | The structural barriers: data sharing and validation
<i>Ralf Omar Floca – DKFZ Heidelberg, Germany</i> |
| 11:20-11:35 | What industry needs from RECIST: enabling better development decisions
<i>Rob Janiczek – Johnson & Johnson, USA</i> |
| 11:35-11:50 | RECIST and regulatory science: credibility, interpretability, consistency
<i>Pierre Denis Démolis – Icelandic Medicines Agency, Iceland</i> |
| 11:50-12:05 | From response to value: the HTA perspective on RECIST
<i>Beate Wieseler – IQWiG, Germany</i> |
| 12:05-12:30 | Panel discussion
<i>Including Erik Briers – Europa Uomo, Belgium and Elena Garralda – Vall d’Hebron Institute of Oncology, Spain</i> |

12:30-13:45 Poster viewing / Lunch

13:45-17:15 Track 4 – International Policy & Regulations

Track Co-Chairs:

Denis Lacombe – EORTC, Belgium

Richard Sullivan – King’s College London, United Kingdom

13:45-15:15 Session 7: Resetting priorities in Clinical Cancer Research: from EU policies to impact (part 1)

- 13:45-13:55 Opening and scene setting
Denis Lacombe – EORTC, Belgium
Richard Sullivan – King’s College London, United Kingdom
- 13:55-14:20 Keynote 1: Balancing commercial and public health needs
Martin Kaiser – The Institute of Cancer Research, United Kingdom
- 14:20-14:45 Keynote 2: Methodological and technical innovation versus policy and regulations: an (ir)reconcilable gap?
Richard Sullivan – King’s College London, United Kingdom
- 14:45-15:10 Keynote 3: Europe in the Global Health Policy Environment
Adrian Gheorghe – Center for Global Development, United Kingdom
- 15:10-15:15 Introducing the panel discussion: objectives and participants
Denis Lacombe – EORTC, Belgium
Richard Sullivan – King’s College London, United Kingdom

15:15-15:45 Poster viewing / Coffee break

15:45-17:15 Session 8: Resetting priorities in Clinical Cancer Research: from EU policies to impact (part 2)

- 15:45-16:15 EU frameworks for clinical research: regulations, policies and looking forward
Joanna Drake – EU Commission DG Research and Innovation, Belgium
- 16:15-17:15 Panel discussion: Optimising stakeholder alignment in research and care
Co-Chairs:
Denis Lacombe – EORTC, Belgium and Richard Sullivan – King’s College London, United Kingdom
Panellists:
Francesco Pignatti – EMA, the Netherlands
Roisin Adams – National Centre for Pharmacoeconomics, Ireland
Yannis Natsis – ESIP, Belgium
Erik Briers – Europa Uomo, Belgium
Winette van der Graaf – Netherlands Cancer Institute, the Netherlands
Lada Leyens – EFPIA, Belgium
Marjolein Geurts – Erasmus MC, the Netherlands

17:15-17:30 Closing remarks

Summit Chair: Benjamin Besse – Institut Gustave Roussy, France
Summit Co-Chair: Elena Garralda – Vall d’Hebron Institute of Oncology, Spain